Pay in 4 interest-free payments of $6.45 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
CagriSema's Advantages: First to Market: 6-12 month head start Leverages Wegovy Success: Built-in brand recognition Proven Semaglutide Component: Half the drug is already approved Strong Diabetes Data: Positions for dual indication No Dysesthesia: Cleaner safety profile in one key area Retatrutide's Advantages: Higher Efficacy: 28.7% vs 20.4% (8.3 points more) Superior BP Reduction: -14 mmHg vs likely similar to semaglutide Single Molecule: Potentially easier manufacturing Multiple Indications: OA, OSA, obesity, diabetes trials Novel Class: First triple agonist = strong IP protection The Verdict: Market Will Support Both These medications won't compete head-to-head
The promise of "12 months of weight loss for one payment" sometimes oversimplifies the ongoing need for medical guidance, potential dose adjustments, and managing side effects
Presently, the Australian Diabetes Society (ADS) and ANZCA Perioperative Diabetes and Hyperglycaemia Guidelines (November 2022) provide the universal recommendation to withhold all non-insulin antihyperglycaemics on day of surgery, including GLP-1 agonists, with SGLT2 inhibitors to be withheld 2 days prior to surgery
People over the age of 14 should consume more than 2.4 micrograms (mcg) of vitamin B-12 daily
doi:10.1089/thy.1995.5.249 172
